DE69333886D1 - Adenovirus-gelenkter Gen-Transfer zum Herz-und glatten vaskulären Muskel - Google Patents

Adenovirus-gelenkter Gen-Transfer zum Herz-und glatten vaskulären Muskel

Info

Publication number
DE69333886D1
DE69333886D1 DE69333886T DE69333886T DE69333886D1 DE 69333886 D1 DE69333886 D1 DE 69333886D1 DE 69333886 T DE69333886 T DE 69333886T DE 69333886 T DE69333886 T DE 69333886T DE 69333886 D1 DE69333886 D1 DE 69333886D1
Authority
DE
Germany
Prior art keywords
adenovirus
gene transfer
heart
vascular muscle
smooth vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69333886T
Other languages
English (en)
Other versions
DE69333886T2 (de
Inventor
Jeffrey M Leiden
Eliav Barr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25525197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69333886(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of DE69333886D1 publication Critical patent/DE69333886D1/de
Application granted granted Critical
Publication of DE69333886T2 publication Critical patent/DE69333886T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
DE69333886T 1992-11-18 1993-11-16 Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel Expired - Fee Related DE69333886T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97749692A 1992-11-18 1992-11-18
US977496 1992-11-18

Publications (2)

Publication Number Publication Date
DE69333886D1 true DE69333886D1 (de) 2006-03-02
DE69333886T2 DE69333886T2 (de) 2006-07-27

Family

ID=25525197

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69333886T Expired - Fee Related DE69333886T2 (de) 1992-11-18 1993-11-16 Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel
DE69331526T Expired - Fee Related DE69331526T2 (de) 1992-11-18 1993-11-16 Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69331526T Expired - Fee Related DE69331526T2 (de) 1992-11-18 1993-11-16 Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel

Country Status (8)

Country Link
US (2) US6297220B1 (de)
EP (3) EP0668913B1 (de)
JP (4) JPH08506008A (de)
AT (2) ATE307212T1 (de)
AU (1) AU694097B2 (de)
CA (1) CA2149771A1 (de)
DE (2) DE69333886T2 (de)
WO (1) WO1994011506A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
AU727970B2 (en) * 1993-05-28 2001-01-04 Transgene S.A. Defective adenoviruses and corresponding complementation lines
AU7404994A (en) * 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
CA2184584C (en) 1994-03-08 2003-04-08 Jing-Shan Hu Vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
FR2718150B1 (fr) 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
AU4502096A (en) * 1994-11-11 1996-06-06 Arch Development Corporation A process of inhibiting non-neoplastic pathological cell proliferation
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EP0760682A4 (de) * 1995-02-28 1998-09-09 Univ California Gentransfer-vermittelte therapie zur gefässneubildung
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6306830B1 (en) 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2222140C (en) 1995-06-15 2010-11-23 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5795872A (en) * 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
US6090618A (en) 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
US7169764B1 (en) 1995-10-05 2007-01-30 Arch Development Corporation Promoter for smooth muscle cell expression
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
JP2000500017A (ja) * 1995-11-17 2000-01-11 ウォルフガンク−エム フランツ 遺伝子治療核酸構造体、その製造と心臓疾患治療へのその利用
US20010009904A1 (en) * 1997-12-30 2001-07-26 Jon A. Wolff Process of delivering a polynucleotide to a cell via the vascular system
JP3930052B2 (ja) 1996-02-15 2007-06-13 バイオセンス・インコーポレイテッド カテーテルに基づく手術
AU2437397A (en) 1996-07-17 1998-02-09 Medtronic, Inc. System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
AU2458597A (en) 1996-07-17 1998-02-09 Medtronic, Inc. System for genetically treating cardiac conduction disturbances
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
AU7250298A (en) * 1997-04-25 1998-11-24 Collateral Therapeutics, Inc. Truncated vegf-related proteins
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
EP2278006A3 (de) 1997-11-06 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Antigene aus Neisseria
US6151525A (en) * 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
US7031775B2 (en) 1997-11-07 2006-04-18 Medtronic, Inc. Method and system for myocardial infarction repair
US6775574B1 (en) 1997-11-07 2004-08-10 Medtronic, Inc. Method and system for myocardial infarction repair
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
EP1645631B1 (de) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neisseria Meningitidis Antigene und Zusammenstellungen
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
AU5819599A (en) * 1998-09-11 2000-04-03 Regents Of The University Of California, The Recombinant adenovirus for tissue specific expression in heart
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
ES2477194T3 (es) 1999-04-30 2014-07-16 Novartis Vaccines And Diagnostics S.R.L. Ant�genos neisseriales conservados
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
DK2275552T3 (en) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Neisserial antigenic peptides
CA2395839A1 (en) 1999-12-27 2001-07-05 The Regents Of The University Of California Gene therapy for congestive heart failure
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
WO2002002148A2 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
FR2811678B1 (fr) * 2000-07-12 2002-09-27 Inst Nat Sante Rech Med Promoteur specifique du myocarde
WO2002011769A1 (en) 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
JPWO2002031138A1 (ja) * 2000-10-06 2004-02-19 株式会社ディナベック研究所 骨格筋に外来遺伝子を導入するためのパラミクソウイルスベクター
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
EP1361896A2 (de) * 2001-01-23 2003-11-19 Boston Scientific Corporation Methode zur lokalen myocardialen injektion zur behandlung ischämischen myocardiums
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
KR20030093316A (ko) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２
EP1451306A1 (de) * 2001-11-06 2004-09-01 Medtronic, Inc. Verfahren und system zur operativen versorgung nach myokardinfarkt
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
DE60329835D1 (de) 2002-04-25 2009-12-10 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
US20040044329A1 (en) * 2002-08-29 2004-03-04 Trudell Leonard A. Catheter for cardiac injection and method for delivery of therapeutic agents to specified tissues
WO2004073484A2 (en) * 2003-02-24 2004-09-02 Yossi Gross Fully-implantable cardiac recovery system
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7818040B2 (en) * 2003-09-05 2010-10-19 Medtronic, Inc. Deflectable medical therapy delivery device having common lumen profile
CN1621094A (zh) * 2003-11-26 2005-06-01 犹太大学阿尔伯特爱因斯坦医学院 用于调节平滑肌张力的基因转移
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
ES2407465T3 (es) 2004-03-29 2013-06-12 Galpharma Co., Ltd. Nueva proteína galectina 9 modificada y uso de la misma
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
ITRM20040569A1 (it) * 2004-11-18 2005-02-18 Biogem S C A R L Biotecnologie Modello animale per lo studio di sostanze ad attivita' cardioterapeutica ed anti-ipertensiva.
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US20070265221A1 (en) * 2006-05-09 2007-11-15 Weiss Robert G Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008103336A1 (en) * 2007-02-21 2008-08-28 Cook Incorporated Methods for intravascular engraftment in heart
CA2715765A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
EP3512567B1 (de) * 2016-09-16 2023-11-01 Icahn School of Medicine at Mount Sinai Zellspezifische expression von modrna

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0456640A1 (de) 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetisch erzeugte endothelzellen und deren verwendung
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
SE464777B (sv) 1989-10-03 1991-06-10 Be Ge Ind Ab Progressiv luftfjaeder
IE911115A1 (en) 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.

Also Published As

Publication number Publication date
US6297220B1 (en) 2001-10-02
EP0957172A3 (de) 2000-03-15
ATE212665T1 (de) 2002-02-15
AU694097B2 (en) 1998-07-16
EP1321526A2 (de) 2003-06-25
JPH08506008A (ja) 1996-07-02
DE69333886T2 (de) 2006-07-27
DE69331526D1 (de) 2002-03-14
ATE307212T1 (de) 2005-11-15
JP2006212034A (ja) 2006-08-17
US6436907B1 (en) 2002-08-20
AU5609394A (en) 1994-06-08
EP0668913A1 (de) 1995-08-30
EP0668913B1 (de) 2002-01-30
CA2149771A1 (en) 1994-05-26
JP2003102474A (ja) 2003-04-08
WO1994011506A1 (en) 1994-05-26
EP1321526A3 (de) 2003-07-02
EP0957172B1 (de) 2005-10-19
JP2004313198A (ja) 2004-11-11
EP0957172A2 (de) 1999-11-17
DE69331526T2 (de) 2002-10-24

Similar Documents

Publication Publication Date Title
ATE307212T1 (de) Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel
FR2681786B1 (de)
GEP20033145B (en) Stem Cell Factor
DE69233010D1 (de) Universale spenderzellen
DE69232983D1 (de) Adeno-assozierter virus 2 basalvektoren
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
AU568067B2 (en) Oligonucleotide therapeutic agent and methods of making same
ATE240401T1 (de) Expression von exogenen polynukleotidsequenzen in wirbeltieren
PT80300A (de) Herstellung von polypeptiden mit human-gammainterferonaktivitat
EP0637966A1 (de) Warte-effekt bei tumorzerstörender therapie.
MY101718A (en) Medicated cosmetic compositions
Schjerling The basics of gene doping
DK0555785T3 (da) Glat-muskel-mitogent stof og DNA, der koder herfor
IL192893A0 (en) Cell-based gene therapy for the pulmonary system
Paçarizi et al. The expression of growth factors in human melanomas
周洁民 et al. Expression of Human Factor Ⅸ cDNA in Mice by Implants of Genetically Modified Skin Fibroblasts From a Hemophilia B Patient
Chung Toxicity of the Adenoviral Vector Mediated Gene Therapy

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee